-+ 0.00%
-+ 0.00%
-+ 0.00%

HELUS PHARMA - TOPLINE DATA FROM PHASE 3 HLP003 STUDY FOR MDD EXPECTED IN Q4 2026

Reuters·08/03/2026 11:40:00

Please log in to view news